The overexpression of spliced oncogenic Ikaros isoforms in Philadelphia-positive (Ph plus) acute lymphoblastic leukemia (ALL) patients is a new mechanism of resistance to tyrosine kinase inhibitors.

被引：0
|
作者：
Iacobucci, I. [1 ]
Lonelti, A. [1 ]
Ottaviani, E. [1 ]
Cilloni, D. [2 ]
Messa, F. [2 ]
Paolini, S. [1 ]
Papayannidis, C. [1 ]
Panagiota, G. [1 ]
Soverini, S. [1 ]
Amabile, M. [1 ]
Poerio, A. [1 ]
Rondoni, M.
Saglio, G. [2 ]
Pane, F. [3 ]
Berton, G.
Baruzzi, A. [4 ]
Vitale, A. [5 ]
Foa, R. [5 ]
Baccarani, M. [1 ]
Martinelli, Giovanni [1 ]
机构：
[1] Univ Bologna, Dept Hematol Oncol L & A Seragnoli, Bologna, Italy
[2] Univ Turin Orbassano, Turin, Italy
[3] Univ Naples Federico 2, Naples, Italy
[4] Univ Verona, I-37100 Verona, Italy
[5] Univ Roma La Sapienza, Rome, Italy
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.722.722
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
722
引用
收藏
页码：221A / 222A
页数：2
相关论文
共 50 条
  • [1] Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance
    Iacobucci, Ilaria
    Lonetti, Annalisa
    Messa, Francesca
    Cilloni, Daniela
    Arruga, Francesca
    Ottaviani, Emanuela
    Paolini, Stefania
    Papayannidis, Cristina
    Piccaluga, Pier Paolo
    Giannoulia, Panagiota
    Soverini, Simona
    Amabile, Marilina
    Poerio, Angela
    Saglio, Giuseppe
    Pane, Fabrizio
    Berton, Giorgio
    Baruzzi, Anna
    Vitale, Antonella
    Chiaretti, Sabina
    Perini, Giovanni
    Foa, Robin
    Baccarani, Michele
    Martinelli, Giovanni
    BLOOD, 2008, 112 (09) : 3847 - 3855
  • [2] Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance (vol 112, pg 3847, 2008)
    Iacobucci, I.
    Lonetti, A.
    Messa, F.
    BLOOD, 2010, 116 (12) : 2196 - 2196
  • [3] The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors
    Iacobucci, Ilaria
    Lonetti, Annalisa
    Ottaviani, Emanuela
    Cilloni, Daniela
    Messa, Francesca
    Paolini, Stefania
    Papayannidis, Cristina
    Piccaluga, Pier Paolo
    Giannoulia, Panagiota
    Soverini, Simona
    Amabile, Marilina
    Saglio, Giuseppe
    Pane, Fabrizio
    Berton, Giorgio
    Baruzzi, Anna
    Vitale, Antonella
    Foa, Robin
    Baccarani, Michele
    Martinelli, Giovanni
    CANCER RESEARCH, 2008, 68 (09)
  • [4] Identification of a new mechanism of resistance to imatinib and dasatinib in PH-positive acute lymphoblastic leukemia: Overexpression of aberrantly spliced oncogenic Ikaros informs
    Iacobucci, I.
    Soverini, S.
    Paolini, S.
    Piccaluga, P. P.
    Rondori, M.
    Ottaviani, E.
    Amabile, M.
    Poerio, A.
    Castagnetti, F.
    Giannoulia, P.
    Colarossi, S.
    Gnari, A.
    Cillori, D.
    Saglio, G.
    Pane, F.
    Rosti, G.
    Baccarani, M.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 2 - 3
  • [5] Intensive chemotherapy with tyrosine kinase inhibitors in philadelphia-positive acute lymphoblastic leukemia
    Benavente, Rafael
    Cid, Fernando
    Puga, Barbara
    Molina, Javiera
    Bass, Francisca
    Andrade, Alejandro
    Monardes, Virginia
    Encina, Andrea
    Elena Cabrera, Maria
    REVISTA MEDICA DE CHILE, 2021, 149 (09) : 1249 - 1257
  • [6] Identification of anew mechanism of resistance to imatinib and dasatinib in PH-positive acute lymphoblastic leukemia (ALL): Overexpression of aberrantly spliced oncogenic wards isoforms
    Iacobucci, I.
    Lonelti, A.
    Soverini, S.
    Paolini, S.
    Piccaluga, P.
    Rondoni, M.
    Ottaviani, E.
    Amabile, M.
    Poerio, A.
    Castagnetti, F.
    Giannoulia, P.
    Colarossi, S.
    Gnani, A.
    Cilloni, D.
    Saglio, G.
    Pane, F.
    Rosti, G. A.
    Baccarani, M.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 4 - 4
  • [7] Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
    Samra, Bachar
    Kantarjian, Hagop M.
    Sasaki, Koji
    Konopleva, Marina Y.
    Khouri, Rita
    O'Brien, Susan M.
    Ferrajoli, Alessandra
    Nunez, Cesar
    Kadia, Tapan M.
    Jabbour, Elias
    BLOOD, 2019, 134
  • [8] Cardiotoxicity of Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients
    Berisha, Adriatik
    Placci, Angelo
    Piccaluga, Pier Paolo
    HEMATO, 2023, 4 (01): : 68 - 75
  • [9] Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors
    Abou Mourad, Yasser R.
    Fernandez, Hugo F.
    Kharfan-Dabaja, Mohamed A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (09) : 949 - 958
  • [10] Pattern and evolution of BCR-ABL kinase domain mutations in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) developing resistance to imatinib.
    Pfeifer, H
    Wassmann, B
    Pavlova, A
    Mueller, M
    Wunderle, L
    Brueck, P
    Oldenburg, J
    Hochhaus, A
    Gschaidmeier, H
    Hoelzer, D
    Ottmann, OG
    BLOOD, 2005, 106 (11) : 46A - 47A
12345